EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Peptic Ulcer Disease

Nimish Vakil

JAMA · 03.12.2024 · 332 (21) · 1832

DOI: 10.1001/jama.2024.19094 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAMA, erschienen am 03.12.2024. Verfasst von Nimish Vakil. Beteiligte Einrichtung: University of Wisconsin School of Medicine and Public Health, Madison. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Helicobacter Infections, Peptic Ulcer, Abdominal Pain. Die Arbeit wurde bisher 134-mal zitiert (Crossref) und nennt 93 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance In the US, peptic ulcer disease affects 1% of the population and approximately 54 000 patients are admitted to the hospital annually for bleeding peptic ulcers. Observations Approximately 10% of patients presenting with upper abdominal pain in a primary care setting have a peptic ulcer as the cause of their symptoms. The principal causes of peptic ulcer disease are Helicobacter pylori infection, which affects approximately 42% of patients with peptic ulcer disease, and aspirin or nonsteroidal anti-inflammatory drug (NSAID) use, which are etiologic factors in approximately 36% of people with peptic ulcer disease. Complications of peptic ulcer include bleeding (73% of patients), perforation (9% of patients), and pyloric obstruction (3% of patients). Annually, 10 000 people die of peptic ulcer disease in the US. Endoscopy definitively diagnoses peptic ulcer disease. Acid blockers, such as omeprazole, can heal peptic ulcers in approximately 80% to 100% of patients within 4 weeks, but gastric ulcers larger than 2 cm may require 8 weeks of treatment. Eradication of H pylori decreases peptic ulcer recurrence rates from approximately 50% to 60% to 0% to 2%. Discontinuing NSAIDs heals 95% of ulcers identified on endoscopy and reduces recurrence from 40% to 9%. When discontinuing an NSAID is not desirable, changing the NSAID (eg, from ketorolac to ibuprofen), adding a proton pump inhibitor such as omeprazole or lansoprazole, and eradicating H pylori with treatment such as bismuth, metronidazole, and tetracycline combined with omeprazole can reduce recurrence rates. Conclusions and Relevance Peptic ulcer disease is associated with increased hospitalization rates and mortality. Acid blocking with proton pump inhibitors, such as omeprazole or lansoprazole, is the primary treatment. Recurrence of ulcers can be prevented by eradicating H pylori if present and discontinuing aspirin or NSAIDs if applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Inflammatory Agents, Non-SteroidalHelicobacter InfectionsPeptic UlcerAbdominal PainHumansAnti-Ulcer AgentsAspirinHelicobacter pyloriProton Pump InhibitorsRecurrenceEndoscopy, GastrointestinalMetronidazoleBismuthDrug Therapy, Combination

Substanzen

Anti-Inflammatory Agents, Non-SteroidalAnti-Ulcer AgentsAspirinProton Pump InhibitorsMetronidazoleBismuth

Autor:innen und Institutionen

  • University of Wisconsin School of Medicine and Public Health, Madison.

Zitieren

APA

Vakil, N. (2024). Peptic Ulcer Disease. JAMA, 332(21), 1832. https://doi.org/10.1001/jama.2024.19094

Vancouver

Vakil N. Peptic Ulcer Disease. JAMA. 2024;332(21):1832. doi:10.1001/jama.2024.19094

BibTeX
@article{Vakil2024,
  author = {Vakil, Nimish},
  title = {Peptic Ulcer Disease},
  journal = {JAMA},
  year = {2024},
  volume = {332},
  number = {21},
  pages = {1832},
  doi = {10.1001/jama.2024.19094}
}
Kostenlos starten →